Septic Shock – Pipeline Review, H1 2012
Reference Code: GMDHC1921IDB
Publication Date: April 2012
Septic Shock – Pipeline Review, H1 2012 GMDHC1921IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Septic Shock – Pipeline Review, H1 2012
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables ................................................................................................................................................................................. 5
List of Figures ................................................................................................................................................................................ 6
Introduction......................................................................................................................................................................................... 7
Global Markets Direct Report Coverage ........................................................................................................................................ 7
Septic Shock Overview....................................................................................................................................................................... 8
Therapeutics Development................................................................................................................................................................. 9
An Overview of Pipeline Products for Septic Shock ...................................................................................................................... 9
Septic Shock Therapeutics under Development by Companies ....................................................................................................... 11
Septic Shock Therapeutics under Investigation by Universities/Institutes ........................................................................................ 12
Late Stage Products ......................................................................................................................................................................... 14
Comparative Analysis .................................................................................................................................................................. 14
Mid Clinical Stage Products.............................................................................................................................................................. 15
Comparative Analysis .................................................................................................................................................................. 15
Early Clinical Stage Products ........................................................................................................................................................... 16
Comparative Analysis .................................................................................................................................................................. 16
Pre-Clinical Stage Products.............................................................................................................................................................. 17
Comparative Analysis .................................................................................................................................................................. 17
Septic Shock Therapeutics – Products under Development by Companies ..................................................................................... 18
Septic Shock Therapeutics – Products under Investigation by Universities/Institutes ...................................................................... 19
Companies Involved in Septic Shock Therapeutics Development.................................................................................................... 20
Baxter International Inc................................................................................................................................................................ 20
Medinox, Inc. ............................................................................................................................................................................... 21
AstraZeneca PLC ........................................................................................................................................................................ 22
Cytokine PharmaSciences, Inc. ................................................................................................................................................... 23
Green Cross Corporation ............................................................................................................................................................ 24
MetrioPharm AG .......................................................................................................................................................................... 25
NovImmune SA ........................................................................................................................................................................... 26
Septic Shock – Therapeutics Assessment ....................................................................................................................................... 27
Assessment by Monotherapy Products ....................................................................................................................................... 27
Assessment by Combination Products ........................................................................................................................................ 28
Assessment by Route of Administration ...................................................................................................................................... 29
Assessment by Molecule Type .................................................................................................................................................... 31
Drug Profiles..................................................................................................................................................................................... 33
CytoFab - Drug Profile ................................................................................................................................................................. 33
Product Description................................................................................................................................................................. 33
Mechanism of Action ............................................................................................................................................................... 33
R&D Progress ......................................................................................................................................................................... 33
NI-0101 - Drug Profile.................................................................................................................................................................. 34
Product Description................................................................................................................................................................. 34
Mechanism of Action ............................................................................................................................................................... 34
R&D Progress ......................................................................................................................................................................... 34
Septic Shock – Pipeline Review, H1 2012 GMDHC1921IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Septic Shock – Pipeline Review, H1 2012
Norathiol - Drug Profile ................................................................................................................................................................ 35
Product Description................................................................................................................................................................. 35
Mechanism of Action ............................................................................................................................................................... 35
R&D Progress ......................................................................................................................................................................... 35
Thiamine - Drug Profile ................................................................................................................................................................ 36
Product Description................................................................................................................................................................. 36
Mechanism of Action ............................................................................................................................................................... 36
R&D Progress ......................................................................................................................................................................... 36
Albumin - Drug Profile ................................................................................................................................................................. 37
Product Description................................................................................................................................................................. 37
Mechanism of Action ............................................................................................................................................................... 37
R&D Progress ......................................................................................................................................................................... 37
Epinephrine - Drug Profile ........................................................................................................................................................... 38
Product Description................................................................................................................................................................. 38
Mechanism of Action ............................................................................................................................................................... 38
R&D Progress ......................................................................................................................................................................... 38
Methylene Blue + Nitric Oxide - Drug Profile ............................................................................................................................... 39
Product Description................................................................................................................................................................. 39
Mechanism of Action ............................................................................................................................................................... 39
R&D Progress ......................................................................................................................................................................... 40
Hydrocortisone - Drug Profile ...................................................................................................................................................... 41
Product Description................................................................................................................................................................. 41
Mechanism of Action ............................................................................................................................................................... 41
R&D Progress ......................................................................................................................................................................... 41
Terlipressin - Drug Profile ............................................................................................................................................................ 42
Product Description................................................................................................................................................................. 42
Mechanism of Action ............................................................................................................................................................... 42
R&D Progress ......................................................................................................................................................................... 42
Arginine Vasopressin - Drug Profile............................................................................................................................................. 43
Product Description................................................................................................................................................................. 43
Mechanism of Action ............................................................................................................................................................... 43
R&D Progress ......................................................................................................................................................................... 43
Recombinant Human Activated Protein C - Drug Profile ............................................................................................................. 44
Product Description................................................................................................................................................................. 44
Mechanism of Action ............................................................................................................................................................... 44
R&D Progress ......................................................................................................................................................................... 44
Recombinant Human Activated Protein C + Hydrocortisone + Fludrocortisone - Drug Profile .................................................... 45
Product Description................................................................................................................................................................. 45
Mechanism of Action ............................................................................................................................................................... 45
R&D Progress ......................................................................................................................................................................... 46
Acetyl-L-Carnitine - Drug Profile .................................................................................................................................................. 47
Product Description................................................................................................................................................................. 47
Mechanism of Action ....................................................................................................................